Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Use of PET-CT in the Management of Crohn's Disease

This study has been terminated.
(PI left the institution)
Information provided by (Responsible Party):
Columbia University Identifier:
First received: August 12, 2010
Last updated: April 9, 2015
Last verified: April 2015
Crohn's disease (CD) is an autoimmune disorder which affects over 700,000 people in the U.S. The disease can vary in severity and multiple drug classes are available to the disease depending on disease severity and complications. Our purpose will be to study how PET-CT scans can be used to better manage Crohn's Disease.

Condition Intervention
Crohn's Disease
Radiation: PET-CT scan

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pilot Study in the Use of Positron Emission Tomography-Computed Tomography (PET-CT)in the Management of Crohn's Disease

Resource links provided by NLM:

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Pravelence of PET activity with high CDAI score. [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    To determine whether baseline PET SUV-max correlates with response to biologic therapy, as measure by CDAI.

Enrollment: 5
Study Start Date: February 2011
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Crohn's disease
Patients will receieve Radiation: PET-CT scan
Radiation: PET-CT scan
PET-CT scan performed at baseline to determine SUV-max
Other Name: Positron emission tomography-computed tomography

Detailed Description:

Crohn's disease (CD) is a gastrointestinal autoimmune disease thought to result from exposure to luminal antigen. This exposure then results in a robust Th1 mediated immune response which is not downregulated, resulting in intestinal tissue injury. Crohn's disease most commonly involves the distal small intestine, a site that can be difficult to visualize given its central location within the gastrointestinal tract.

A substantial proportion of patients do not respond to any of the standard therapies. Over 40% of patients do not respond to an initial anti-TNF (biologic) agent and approximately 10% per year lose their response to these drugs. There is no standard definition of what constitutes a patient who has primary biologic failure.

Disease activity is measured by indices such as the Crohn's Disease Activity Index (CDAI). The CDAI includes a combination of clinical criteria and lab values. However, the CDAI is limited by reliance on subjective criteria, limiting the score's use as a valid measure of studying response to medical therapy. Clinically, reliance on CDAI can result in inappropriate continuation of an ineffective therapy resulting in worsening of underlying disease, and increasing risk of adverse reactions.

Small studies have demonstrated that PET scans may accurately quantify disease activity in Crohn's. We propose to study CD patients with active flares to assess for a correlation between PET activity and CDAI. Additionally, we will determine whether PET signal intensity is predictive of clinical response to therapy with biologic agents.

The study proposes to test the hypothesis that PET can be used to determine which CD patients with small bowel disease will be true responders (or nonresponders) to biologic therapy at week 12. The use of PET to determine response to biologic therapy in small bowel Crohn's disease would be novel.


Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All adults between ages of 21-65 who have previously been diagnosed with Crohn's disease

Inclusion Criteria:

  • Diagnosis of Crohn's disease
  • CDAI1>220
  • Identification of small bowel disease based on an imaging study (CT scan, Abdominal ultrasound, MRI), colonoscopy, or histopathology 4. Need for initiation of biologic therapy to control disease process.

Exclusion Criteria:

  • Abdominal surgery within 8 wks of study entry
  • Change in dose of steroids or immunomodulators within 2wks of study entry
  • Pregnancy
  • Active bacterial infection or undrained abscess
  • Any contraindications to initiation of AntiTNF therapy (i.e. latent tuberculosis).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01182467

United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Principal Investigator: Arun Swaminath, MD Columbia University
Principal Investigator: Masanori Ichise, MD Columbia University
  More Information

Responsible Party: Columbia University Identifier: NCT01182467     History of Changes
Other Study ID Numbers: AAAE8300 
Study First Received: August 12, 2010
Last Updated: April 9, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
Inflammatory bowel disease, PET scan, Crohn's disease

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases processed this record on October 21, 2016